Yumanity Therapeutics is transforming drug discovery for neurodegenerative diseases caused by protein misfolding. Formed in 2014 by renowned biotech industry leader, Tony Coles, M.D., and protein folding science pioneer, Susan Lindquist, Ph.D., the company is initially focused on discovering disease-modifying therapies for patients with Alzheimer's disease, Parkinson's disease and amyotrophic lateral sclerosis (ALS). Leveraging its three integrated platforms, Yumanity's innovative new approach to drug discovery and development concentrates on reversing the cellular phenotypes and disease pathologies caused by protein misfolding.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 02/10/16 | $45,000,000 | Series A |
Alexandria Real Estate Equities Biogen Idec Dolby Family Ventures Fidelity Management & Research Company Redmile Group Sanofi-Genzyme BioVentures | undisclosed |
